Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02904798 · ClinicalTrials.gov registry record · NA
The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos
A NA study of Photodermatoses, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT02904798: Completed NA study of Photodermatoses, sponsored by Henry Ford Health System.
NCT02904798 is a NA study of Photodermatoses that has completed, run by Henry Ford Health System. The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02904798, a NA study of Photodermatoses, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
Polypodium Leucotomos Extract (PLE) is a tropical fern that has antioxidative, photoprotective, chemoprotective, anti-inflammatory, and immunomodulatory properties. The antioxidative effects of PL include inhibition and scavenging of free radicals, lipid peroxidation and reactive oxygen species (ROS) such hydrogen peroxide, superoxide anion, hydroxyl radical and singlet oxygen. Visible light (400-700 nm) causes pigmentation in melanocompetent individuals and induces DNA damage in the human skin through ROS production. The goal of this study is to determine whether the administration of oral PLE has an effect on the development of visible light induced pigmentation.
Primary Outcome
Detect differences in visible light induced pigmentation pre and post PLE using the following" 1. Investigator Global Assessment Scoring 2. Diffuse Reflectance Spectroscopy 3. Colorimetry 4. Biopsy with melanocyte and melanin stains among other tissue markers 5. Photography
Conditions Studied
Interventions
- DRUG Polypodium Leucotomos
Study Locations (1)
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2017-04-23 |
| Phase | NA |
What the finished NCT02904798 record still lists
NCT02904798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Photodermatoses appearing as the primary indexed condition, and to 1 intervention - of which Polypodium Leucotomos is the first listed.
NCT02904798 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02904798 about?
NCT02904798 is a clinical study titled "The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos". Polypodium Leucotomos Extract (PLE) is a tropical fern that has antioxidative, photoprotective, chemoprotective, anti-inflammatory, and immunomodulatory properties. The antioxidative effects of PL include inhibition and scavenging of free radicals, lipid peroxidation and reactive oxygen species (ROS...
What is the current status of trial NCT02904798?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2015-07-01. Estimated completion is 2017-04-23.
What conditions does trial NCT02904798 study?
This clinical trial studies the following conditions: Photodermatoses.
What interventions are being tested in trial NCT02904798?
The interventions under investigation include: Polypodium Leucotomos (DRUG).
Who is sponsoring clinical trial NCT02904798?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02904798 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02904798's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI